Both PD-L1 inhibitor monotherapy (tpos-pdl1t) and combination therapy (tpos-um-pdl1t) groups exhibited significant reductions in tumor volume (p < 0.001) and mass (p < 0.001) (Figure 1b,c) and prolonged survival (p < 0.01) compared to ck and USMC-only groups (Figure 1d). This evidence concerns the gene CD274 and neoplasm.